Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00032890 · ClinicalTrials.gov registry record · Phase 3

Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)

A Phase 3 study of Osteoarthritis, sponsored by US Department of Veterans Affairs.

Completed
Registry status
Phase 3
Development phase
1,588
Enrollment target
16
Study locations

NCT00032890 is a Phase 3 study of Osteoarthritis that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 1,588 participants, above the 806-participant average among 135 other Osteoarthritis trials with a reported enrollment target (97% higher). The trial reports 16 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00032890, a Phase 3 study of Osteoarthritis, has completed, sponsored by US Department of Veterans Affairs.

COMPLETED
Registry status
Phase 3
Development phase
1,588 participants
Enrollment target
16
Study locations

Study Summary

This study will determine whether glucosamine, chondroitin sulfate and/or the combination of glucosamine and chondroitin sulfate are more effective than placebo and whether the combination is more effective than glucosamine or chondroitin sulfate alone in the treatment of knee pain associated with osteoarthritis (OA) of the knee after six months of follow-up. These substances, marketed in the United States as dietary supplements, have been widely touted by the lay press and by anecdotal personal experience as effective in treating OA. To date, however, only a few small studies have been published in the worldwide literature. The study proposed herein has been carefully constructed to definitively determine the efficacy of these agents.

Conditions Studied

Osteoarthritis

Interventions

  • DRUG celecoxib
  • DRUG glucosamine
  • DRUG chondroitin sulfate
  • DRUG glucosamine and chondroitin sulfate combined

Study Locations (16)

California

  • *Cedars-Sinai Medical Center - Los Angeles
  • *University of California, Los Angeles - Los Angeles
  • *University of California San Francisco - San Francisco

Pennsylvania

  • University of Pennsylvania - Philadelphia
  • *University of Pittsburgh - Pittsburgh

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • *University of Arizona Arthritis Center - Tucson

Illinois

  • Northwestern University - Chicago

Indiana

  • *Indiana University School of Medicine - Indianapolis

Kansas

  • *Arthritis Research and Clinical Centers - Wichita

Nebraska

  • University of Nebraska Medical Center - Omaha

Trial Details

FieldValue
Enrollment Target 1,588 participants
Start Date 2000-04
Est. Completion 2004-02
Phase Phase 3

Sponsor

US Department of Veterans Affairs

632 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00032890

The ClinicalTrials.gov registry entry for NCT00032890 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,588 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 806-participant average among 135 other Osteoarthritis trials with a reported enrollment target (97% higher). The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 4 interventions - of which celecoxib is the first listed.

NCT00032890 reports 16 study locations spanning 13 distinct geographic areas - top geographies include California, Pennsylvania, Alabama.

Frequently Asked Questions

What is clinical trial NCT00032890 about?

NCT00032890 is a clinical study titled "Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)". This study will determine whether glucosamine, chondroitin sulfate and/or the combination of glucosamine and chondroitin sulfate are more effective than placebo and whether the combination is more effective than glucosamine or chondroitin sulfate alone in the treatment of knee pain associated with o...

What is the current status of trial NCT00032890?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,588 participants. The study started on 2000-04. Estimated completion is 2004-02.

What conditions does trial NCT00032890 study?

This clinical trial studies the following conditions: Osteoarthritis.

What interventions are being tested in trial NCT00032890?

The interventions under investigation include: celecoxib (DRUG), glucosamine (DRUG), chondroitin sulfate (DRUG), glucosamine and chondroitin sulfate combined (DRUG).

Who is sponsoring clinical trial NCT00032890?

This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00032890 being conducted?

This trial has 16 study locations across Alabama, Arizona, California, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Osteoarthritis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.